Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of Relacorilant in Healthy Subjects
NCT03067376Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Aug 2016
- Primary completion
- Sep 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of relacorilant in Cushing's syndrome, sponsored by Corcept Therapeutics. Primary endpoints: Amount of radioactivity eliminated in urine, Amount of radioactivity eliminated in feces and 13 more. Started Aug 2016; status: completed.
02
Drugs
relacorilant
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT03067376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03067376.